Aspen Pharmacare Holdings Limited · JSE:APN

Aspen Pharmacare — H1 2010 Earnings Presentation

51 slides from Aspen Pharmacare's earnings presentation, March 2010

  1. Slide 1: Interim Results for the Six Months ended 31 December 2009

    Interim Results for the Six Months ended 31 December 2009

  2. Slide 2: Statement of Comprehensive Income Re-analysed

    STATEMENT OF COMPREHENSIVE INCOME RE-ANALYSED 6 Months 6 Months % Ended Ended Change 31 Dec 2009 31 Dec 2008 Revenue from continuing operations 4R’m 576 4 142 R’m10% Cost of Sales (2 441) (2 232) Gross Profit 2 135 1 910 12% Net operating expenses (925) (730) Other operating income 151 4 EBITA 1 361

  3. Slide 3: The GSK Transactions

    THE GSK TRANSACTIONS Completed 1 December 2009 Contribution for one month – in line with guidance 68.5 million ordinary shares issued at R66.80 per share Transaction value of R4.6 billion Goodwill of R300 million South African transaction: • 100% of revenue disclosed by Aspen Sub-Saharan Africa coll

  4. Slide 4: Analysis of Segmental Revenue

    ANALYSIS OF SEGMENTAL REVENUE 31 December 2009: 31 December 2008: Sub-Saharan R4.626bn Africa R4.142bn Sub-Saharan Africa 6% 11% South Africa South Africa 55% 50% International International Operations 39% 39% 4

  5. Slide 5: Revenue by Market – Domestic Brands

    REVENUE BY MARKET – DOMESTIC BRANDS 6 Months 6 Months % Ended Ended Change 31 Dec 2009 31 Dec 2008 R’m R’m SOUTH AFRICA 2 550 2 066 23% South Africa - Pharmaceuticals 1 975 1 525 30% South Africa - Consumer 575 541 6% SUB-SAHARAN AFRICA 279 464 -40% INTERNATIONAL 974 917 6% Asia Pacific 522 484 8% L

  6. Slide 6: Revenue by Market – Global Brands

    REVENUE BY MARKET – GLOBAL BRANDS 6 Months 6 Months % Ended Ended Change 31 Dec 2009 31 Dec 2008 R’m R’m Asia Pacific 227 159 43% Latin America 154 110 40% EMENA 414 393 5% Rest of the World 29 34 -15% Total 824 696 18% 6

  7. Slide 7: Analysis of Segmental EBITA

    ANALYSIS OF SEGMENTAL EBITA 31 December 2009: 31 December 2008: R1.361bn Sub-Saharan Africa 3% R1.184bn Sub-Saharan Africa 8% International South Africa International 37% South Africa 60% 49% 43% 7

  8. Slide 8: Segmental Margins

    SEGMENTAL MARGINS 6 Months 6 Months Ended Ended 31 Dec 2009 30 June 2009 SOUTH AFRICA * 29% 26% South Africa - Pharmaceuticals 32% 29% South Africa - Consumer * 17% 18% SUB-SAHARAN AFRICA 16% 17% INTERNATIONAL 27% 28% GROUP * 28% 26% * EBITA % has been normalised to exclude compensation for loss of

  9. Slide 9: Funding Costs

    FUNDING COSTS 6 Months 6 Months Ended Ended 31 Dec 2009 31 Dec 2008 R’m R’m Interest paid 281 311 Interest received (91) (116) Net interest 190 195 Preference share dividends 14 21 Notional interest on financial instruments 1 (3) Foreign exchange and fair value losses/(gains) (32) 26 Net funding cos

  10. Slide 10: Abridged Balance Sheet

    ABRIDGED BALANCE SHEET 6 Months Year Ended Ended 30 June 2009 ASSETS 31 Dec 2009 R’m R’m Non-current assets 11 564 6 921 Tangible fixed assets 2 952 2 374 Goodwill 688 398 Intangible assets 7 850 4 104 Investment in associates 21 22 Other non-current assets 53 23 Current assets 4 593 3 536 Cash 1 96

  11. Slide 11: Abridged Cash Flow Statement

    ABRIDGED CASH FLOW STATEMENT 6 Months 6 Months % Ended Ended Change 31 Dec 2009 31 Dec 2008 R’m R’m Cash flows from operating activities Cash operating profit 1 482 1 328 12% Working capital requirements (316) (297) 6% Cash generated from operations 1 166 1 031 13% Net funding costs paid (190) (301)

  12. Slide 12: Key Ratios

    KEY RATIOS 6 Months Year Ended 6 Months Ended 30 June 2009 Ended 31 Dec 2008 31 Dec 2009 Gross margin % 46% 46% 47% EBITA % 29% 27% *28% Gearing 59% 51% 29% Net debt / EBITDA 2.3x 1.9x 1.5x Net interest cover 6x 6x 7x Return on shareholders equity (annualised) 38% 38% 38% Working capital as a % of t

  13. Slide 13: 2010 Performance Factors

    2010 PERFORMANCE FACTORS Septemb YTD 6 Months er Actua to June Presentat l 2010 ion Effect of increase in SEP in + SA + + – Organic growth in SA + + + Production capacity + + + unlocked + Neutr + Completion of GSK – al + transactions ? Neutr ? Transition of Global brands x al + Relative currencies –

  14. Slide 14: Distribution of Fund Managers

    DISTRIBUTION OF FUND MANAGERS As at December As at June As at December 2008 2009 2009 Other Other Europe Other 1% Asia 1% Europe 1% 11% Europe Pacific Asia 15% 24% 2% Pacific 2% USA & Canada Asia 19% Pacific 2% USA & South Canada Africa South 23% South USA & 49% Africa Africa Canada 67% 59% 24% 14

  15. Slide 15: Aspen Group – The Headlines

    ASPEN GROUP – THE HEADLINES Aspen group sales has shown strong volume and value growths: • Global brands and Aspen South Africa overperforming • Latam and sub-Saharan Africa underperforming Results underpinned by strong cash flows: • Reduced funding costs Relative Rand hedge element displayed: • Str

  16. Slide 16: Aspen in South Africa

    Aspen in South Africa

  17. Slide 17: Aspen in South Africa - Introduction

    ASPEN IN SOUTH AFRICA - INTRODUCTION Aspen’s legacy stretches back over 150 years in South Africa, linking back to Lennon in 1850 Through a passionate and committed team, the Group has achieved exceptional growth over the last 12 years: • CAGR of over 40% per annum Aspen is South Africa’s number 1 p

  18. Slide 18: Aspen in South Africa - Introduction

    ASPEN IN SOUTH AFRICA - INTRODUCTION Aspen is one of the top 20 generic manufacturers worldwide Aspen is arguably the largest manufacturer in the Southern Hemisphere, manufacturing in excess of 8 billion tablets with the capability of manufacturing, inter alia: • Steriles, lyophilised vials, liquids

  19. Slide 19: Aspen's Performance in South African Market

    ASPEN’S PERFORMANCE IN SOUTH AFRICAN MARKET Aspen has had an outstanding start in this financial year: • Sales ↑ 23% • Operating Profit ↑ over 50% Pharma business continues its growth trajectory: • Price and volume increases • Favourable exchange rate GSK business included for one month: • Business

  20. Slide 20: The Market Performance

    THE MARKET PERFORMANCE Total Private Market as at December 2009 R21.08bn (December 2008 – TPM R18.56bn) OTC R5.80bn Ethical/Branded R11.08 bn Generic R4.20bn 20

  21. Slide 21: The Market Performance

    THE MARKET PERFORMANCE South African Private Market Growth as per IMS – December 2009 MARKET ASPEN +14 +18 Total % % +18 +15 Generic % % +12 +18 OTC % % +13 +24 Branded % % Generics continue to outpace the market 21

  22. Slide 22: Aspen in the South African Market

    ASPEN IN THE SOUTH AFRICAN MARKET harma Market MAT Rand Share % as per IMS – December 2009 ASPEN/GSK ADCOCK INGRAM SANOFI-AVENTIS PFIZER NOVARTIS ASTRAZENECA CIPLA MEDPRO MERCK & CO 16.2 16 ed at 14 or rp 12.6 12.7 12.7 12.8 12.8 12.7 12.7 12.8 12.8 12.5 12.5 co in 12 K GS 10.2 10.4 10.3 10.2 10.1 1

  23. Slide 23: Generic Performance in the South Africa Market

    GENERIC PERFORMANCE IN THE SOUTH AFRICA MARKET can Private Market MAT Rand Share % (Sch 3-7) as per IMS – Decem MAT GENERIC MAT ETHICAL 80 73.26 73.05 73.04 73.03 72.90 72.85 72.83 72.82 72.72 72.57 72.52 72.49 70 60 50 40 30 27.51 27.48 27.43 27.28 27.17 27.18 27.15 27.10 26.97 26.95 26.96 26.74 20

  24. Slide 24: Performance in the South African Generic Market

    PERFORMANCE IN THE SOUTH AFRICAN GENERIC MARKET Generic Market MAT Rand Share % as per IMS – December 2009 Daiichi LupinSankyo Labs 3.75% Pfizer 3.52% 4.10% Aspen 33.65% Adcock 10.56% Novartis 10.72% Cipla 17.92% Other 15.78% Market share lost in first quarter due to strike – recaptured in second qu

  25. Slide 25: Aspen in the South African Market

    ASPEN IN THE SOUTH AFRICAN MARKET anded Market MAT Rand Share % as per IMS – December 2009 SANOFI-AVENTIS ASPEN/GSK ASTRAZENECA PFIZER MERCK & CO ROCHE NOVARTIS ADCOCK/PARKE MED 13 12.28 12.30 12.37 12.12 12.16 12.12 12.15 12.19 12.22 11.91 11.97 12.00 12 GSK consolidated retrospectively 11 10.40 10

  26. Slide 26: Aspen in the South African Market

    ASPEN IN THE SOUTH AFRICAN MARKET OTC Market MAT Rand Share % as per IMS – December 2009 ADCOCK INGRAM ASPEN JOHNSON & JOHNSON SANOFI-AVENTIS PFIZER CIPLA MEDPRO NOVARTIS 18.8 18.7 18.7 18.6 18.7 18.8 18.7 18.8 18.9 19 18.5 18.6 18.5 17 15.1 15.2 15.3 15.4 15.4 15.5 15.3 15.4 14.7 14.8 15.0 15 14.6

  27. Slide 27: Aspen's South African Model

    ASPEN’S SOUTH AFRICAN MODEL le Pip o p eli Pe n e ts u c o d Pr Co Aspen has a simple model Business is simple – We don’t st 27

  28. Slide 28: Field Force Size in South Africa

    ASPEN’S STRENGTH OF REPRESENTATION FIELD FORCE SIZE IN SOUTH AFRICA People CUSTOMER SEGMENT ASPEN RESOURCES Prescribing GP’s Dispensing GP’s 275 Representatives Private Sector Pharmacies Specialists Private Hospitals Key Accounts 9 Key Account Managers Funders and their intermediaries 3 Key Account

  29. Slide 29: Top 20 Therapeutic Classes – 1st Ten

    TOP 20 THERAPEUTIC CLASSES – 1ST TEN Products/Pipeline MAT 11/2009 VALUE GROWT SHARE H Selected Market Segment 20,871,40 13.4 100.0 9 N2B Non-Narcotic Analgesics 1,218,35 16.7 5.8 8 Aspen Group 186,093 22.4 15.3 Aspen has a presence in A2B Antiulcerants 678,424 18.4 3.3 19 Aspen Group 104,718 31.2 1

  30. Slide 30: Top 20 Therapeutic Classes – 2nd Ten

    TOP 20 THERAPEUTIC CLASSES – 2ND TEN Products/Pipeline MAT 11/2009 VALUE GROWTH SHARE Selected Market Segment 20,871,40 13.4 100.0 9 N3A Anti-Epileptics 359,082 20.4 1.7 Aspen Group 49,761 26.3 2.4 J1D Cephalosporins + 350,949 11.5 1.7 Combs Relevance of range Aspen Group 74,829 -5.4 21.3 displayed

  31. Slide 31: Aspen in the South African Private Market

    ASPEN IN THE SOUTH AFRICAN PRIVATE MARKET Result of having the best people and relevant, quality products NO. OF MANUFACTURER % SHARE 60,000,000 SCRIPTS 1 in approximately 4 script lines ASPEN/GSK 50,289,176 23.8% 50,000,000 dispensed are for Aspen/GSK brands ASPEN PHARMACARE 44,709,665 21.1% ADCOCK

  32. Slide 32: Global Cost Competitiveness – Focus on Cost of Goods

    GLOBAL COST COMPETITIVENESS – FOCUS ON COST OF GOODS Technical Heritage Centre facility SVP facility OSD 2 SVP OSD 1 Warehouse Packing OSD 1 Manufactur e Realising the benefits of our ambitious build plan ity Doubling capacity in OSD 1 ric f • 7% incremental cost e ct o % • Can double this again El

  33. Slide 33: Focus on Global Cost Competitiveness

    FOCUS ON GLOBAL COST COMPETITIVENESS Result of cost reductions – RT289 Solid Tender Daiichi Biogaran 5% Cipla 3% Sankyo 3% Dezzo 2% Sandoz 2% Pharmache Aspen/GSK m 2% 30% Adcock 3% Biotech 2% Gulf Drug 4% 2009 Daiichi Biogaran Multinationa Sankyo 4% Cipla 6% Aspen 20% 4% ls 19% Sandoz 1% Other 25% P

  34. Slide 34: Prospects for the Next Six Months

    PROSPECTS FOR THE NEXT SIX MONTHS Volume increases to continue SEP price increase was in February 2009: • SEP increase in April/May 2010? • Relative increase versus last year will not include the same price effect Incorporation of GSK business: • Will add about R400 million to sales for next six mon

  35. Slide 35: Prospects – Aspen in the South African Market

    PROSPECTS – ASPEN IN THE SOUTH AFRICAN MARKET For an additional challenge now we have We have said historically: added a new ball for the team “The greatest reward for those of us working within Aspen is the ability to successfully juggle” Our own social contract of commitment to providing quality,

  36. Slide 36: Aspen in Sub-Saharan Africa

    cleat In Sub-Saharan Diary RE Pr

  37. Slide 37: Rest of Sub-Saharan Africa (SSA)

    REST OF SUB-SAHARAN AFRICA (SSA) Current interest in SSA is in following broad categories: Export from South Africa: • Negatively affected by ARV genericisation: ~Commitment to procure API from licensor • Pipeline focus on hormonals, IMF, OTC and other niche products • Have infrastructure / capabili

  38. Slide 38: Shelys Africa & Aspen Exports

    SHELYS AFRICA & ASPEN EXPORTS Six Months to December 2009 SHELYS/BETA • Shelys Africa consists of: ~Shelys Pharmaceuticals (Tanzania) ~Beta Healthcare (Kenya & Uganda) ~Shelys Export – (focus on Southern/East Africa) BETA 41 • Sales force is in-house and contract rep ASPEN reps EXPORT R48m teams S S

  39. Slide 39: GSK Aspen Healthcare for Africa

    GSK ASPEN HEALTHCARE FOR AFRICA Calendar Year 2009 – Annual Sales • Extensive cover of 4 regions: ~FWCA – 15 countries ~AWA – 5 countries ~EA – 9 countries ~StnA – 9 countries FWCA 70 reps $30m AWA 90 • Sales teams mostly in-house reps $48m • Some regions have additional contract / wholesale teams t

  40. Slide 40: Aspen in Rest of Sub-Saharan Africa (SSA)

    ASPEN IN REST OF SUB-SAHARAN AFRICAN (SSA) These territories are particularly difficult to trade in Individual territory market sizes are generally too small to warrant individual company representation Supply chain including distribution and collection are significant barriers to entry Have market

  41. Slide 41: An investment with Aspen means investing in Africa's number 1 pharma company

    An investment with Aspen means not only investing South Africa’s number 1 Pharma Company, but South Africa and the rest of Sub Saharan Africa’s number 1

  42. Slide 42: Aspen in Latam

    Aspen in Latam

  43. Slide 43: Aspen in Latam

    ASPEN IN LATAM Latam Sales by Territory - Six Months December 2009 : R500 million Venezuela 11% Mexico 16% Brazil 68% Chile 1% Argentina 1% Colombia 3% Global brands constitute 31% of sales 43

  44. Slide 44: Aspen in Latam

    ASPEN IN LATAM Exercised option on balancing 49%: • Awaiting regulatory approval Strides to pay ± $75 million to Aspen for Campos and other assets: • Facility better fit for Strides’ global strategy • Under recovers within Aspen infrastructure • Strides better positioned to manage commodity markets

  45. Slide 45: Aspen in Latam

    ASPEN IN LATAM Further insulin registrations: • Will make a contribution to the second half results Brazil expected to return to profitability for the next six months: • Result of restructuring • Non-recurrence of current period once-off expenses • Profitability enhanced through: ~Pipeline launch ~S

  46. Slide 46: Aspen in Latam

    ASPEN IN LATAM Mexico 99 reps Increased representation in Mexico and Venezuela Venezuela: 27 reps • Support Global brands Colombia • Support own dossiers Ecuador Brazil Moved a team to be headquartered in Peru 123 reps Colombia: • Will include Venezuela • Colombia, Chile, Ecuador, Peru and Argentina

  47. Slide 47: Aspen in Asia Pacific

    Aspen in Asia Pacific

  48. Slide 48: Aspen in Asia Pacific

    ASPEN IN ASIA PACIFIC Asia Pacific Sales By Territory Australia – 72% of sales Six Months to December 2009 : Asia will continue to grow: R748 million • Aspen Asia fully functional Thailand 2% Taiwan 3% • Head quarters in Hong Kong Malaysia 2% Other 3% Indonesia • Volumes in Japan up by Philippines2%

  49. Slide 49: Aspen in Asia Pacific - Prospects

    ASPEN IN ASIA PACIFIC - PROSPECTS Additional growth from further licensing agreements and pipeline: • Will add to the second half of financial year Reviewing opportunities in South East Asia: • Intention to establish infrastructure in Philippines • Base to supply ASEAN market • Regulatory harmonisat

  50. Slide 50: Summary and Prospects

    SUMMARY AND PROSPECTS Currency balance demonstrated: • Will continue into the future • Shift balance between South Africa and Global contributions GSK transactions to be included in next six months: • Contribute to both sales and operating income • Anticipate sales of nearly R900 million in the next

  51. Slide 51: Summary and Prospects

    SUMMARY AND PROSPECTS Sub-Saharan Africa: • GSK Aspen Healthcare commences and will be the major contributor • Focus on pipeline enhancement with over 1000 filings planned in next 12 months Latam: • Restructured and reshaped ~Expect positive performance for the next six months Asia Pacific: • Contin

Aspen Pharmacare Holdings — H1 2010 Earnings Presentation on 6ix